Clinical Trials Directory

Trials / Terminated

TerminatedNCT00276445

Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan

Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan - A Double-Blind Randomized Study

Status
Terminated
Phase
Phase 4
Study type
Interventional
Enrollment
60 (planned)
Sponsor
Meiji University of Oriental Medicine · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Accepted

Summary

Intravenous- injection of beta-1,3-glucan in human is known to induce T helper type 1 response, while oral uptake did not. It was examined whether superfine dispersed beta-1,3-glucan (SDG) contrived to absorbed by intestinal mucosa would alleviate allergic symptoms by per-oral ingestion

Detailed description

Beta-1,3-glucan made from Japanese mushroom is commercially available for healthy foodstuffs. Allergy patients were orally administrated either SDG (n=30) or non-dispersed beta-1,3-glucan (NDG, n=30) and allergic symptoms were assessed clinically, by the double-blind, placebo-controlled, randomized study

Conditions

Interventions

TypeNameDescription
DRUGbeta-1,3-glucan

Timeline

Start date
2004-01-01
Completion
2004-06-01
First posted
2006-01-13
Last updated
2006-11-07

Locations

1 site across 1 country: Japan

Source: ClinicalTrials.gov record NCT00276445. Inclusion in this directory is not an endorsement.

Alleviation of Cedar Pollen Induced Allergic Symptoms by Orally Taken Superfine Beta-1,3-Glucan (NCT00276445) · Clinical Trials Directory